Cleo Diagnostics (ASX:COV) said alpha testing for its ovarian cancer pre-surgical triage test kit has been completed, according to a Monday Australian bourse filing.
The testing marks a critical step along its manufacturing pathway towards commercial production, the filing said.
The testing confirmed differentiation of benign versus malignant ovarian disease, consistent with its previously published studies.
The company's shares fell past 1% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.